Low-grade serous primary peritoneal carcinoma

Gynecol Oncol. 2011 Jun 1;121(3):482-6. doi: 10.1016/j.ygyno.2011.02.017. Epub 2011 Mar 11.


Objective: 10% of women with serous ovarian cancer have low-grade carcinomas. These patients are diagnosed at a younger age, have a longer overall survival and a lower response rate to platinum-based chemotherapy compared to women with high-grade serous ovarian carcinoma. It remains unclear if these features are similar in women with low-grade primary peritoneal cancer (PPC). To further explore this issue, a retrospective analysis of the clinical and pathologic characteristics of women with low-grade serous PPC was performed.

Methods: A retrospective study of 53 patients with low-grade serous PPC evaluated at a single institution from 1986 to 2009 was performed. All cases were reviewed by a gynecologic pathologist to confirm low-grade serous PPC.

Results: Median age at diagnosis was 51.7 years (range 27.1-82.4). 46 patients (86.8%) underwent primary surgery, with optimal tumor reduction achieved in 30 patients (65.2%). 48 patients (90.6%) received chemotherapy as part of their initial treatment. At the completion of primary treatment, 66.7% of patients were noted to have persistent or progressive disease. With a median follow-up of 66.1 months, the 5-year PFS was 16%, yet the 5-year OS was 69%.

Conclusion: To our knowledge, this is the first report of women with low-grade serous PPC. Similar to low-grade serous ovarian carcinoma, patients with low-grade serous PPC have high rates of persistent disease at the completion of primary treatment yet a long overall survival. Further study focusing specifically on low-grade serous ovarian and primary peritoneal carcinomas is needed to determine the optimal treatment of these diseases.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Cystadenocarcinoma, Serous / pathology*
  • Cystadenocarcinoma, Serous / therapy
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Peritoneal Neoplasms / pathology*
  • Peritoneal Neoplasms / therapy
  • Retrospective Studies